Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What Future CAGR is Anticipated for the Iron Deficiency Injectable Market Over the 2025–2034 Period?
The market size for injectable iron deficiency treatments has seen a robust growth in the previous years. Predictions suggest that it will expand from $14.06 billion in 2024 to $15.37 billion in 2025, displaying a compound annual growth rate (CAGR) of 9.3%. This substantial growth during the historic period can be credited to the high incidence of iron deficiency anemia treatments, patients undergoing bariatric surgery, pediatric and adolescent patients and increased instances of pregnancy.
In the coming years, the market size of injectable treatment for iron deficiency is predicted to experience swift expansion. It is projected to reach a market value of $23.13 billion in 2029, expanding at a compound annual growth rate (CAGR) of 10.8%. Factors contributing to the projected growth include an increase in the elderly population, global health movements, government strategies, growing treatments for persistent health conditions, and speedy replenishment of iron. The forecast period is also expected to witness several trends such as improvements in iron formulations, progress in digital health solutions, advancements in therapy involving iron deficiency injectables, and a growing preference for iron-based medications.
Which Drivers Are Expected to Have the Greatest Impact on the iron deficiency injectable Market’s Growth?
The iron deficiency injectables market is projected to expand, fuelled by the growing incidence of polycystic ovary syndrome (PCOS). PCOS is a widespread hormonal condition primarily affecting ovary-having individuals in their reproductive age. It typically causes an iron overload leading to substantial menstrual blood loss, eventually resulting in anaemia. This condition can be treated with iron deficiency injectable medications. For example, in June 2023, the World Health Organization, a US-based health-specific agency, stated that PCOS affects approximately 8-13% of women of reproductive age worldwide, with 70% remaining undetected. The rising incidence of PCOS is thus bolstering the growth of the iron deficiency injectables market. Elevating the growth of the iron deficiency injectable market is the towering prevalence of malnutrition. Malnutrition constitutes a health disorder marked by a disparity between the consumption of vital nutrients and the body’s nutritional requisites. Iron deficiency injectables are dispensed to malnourished patients to instantly replenish the body’s iron reserves and provide a high concentration of iron, which is promptly assimilated into the bloodstream for rapid rectification of the deficiency. For instance, in March 2023, the California Department of Public Health, a US-based governmental state agency, reported that the number of malnutrition-related deaths had escalated to 1,406 in 2022. This figure represented a 22.36% increase compared to the 1,149 deaths in 2021. Hence, the burgeoning incidence of malnutrition is projected to catalyze the growth of the iron deficiency injectable market in the future.
Get Your Free Sample of the Global Iron Deficiency Injectable Market Report Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=12907&type=smp
Who Are the Influential Players Fueling Innovation and Growth in the Iron Deficiency Injectable Market?
Major companies operating in the iron deficiency injectable market are:
• Daiichi Sankyo Company Limited_x000D_
• Pfizer Inc._x000D_
• Aetna Inc._x000D_
• AbbVie Inc._x000D_
• Bayer AG_x000D_
What Impact Are Industry Trends Having on the Iron Deficiency Injectable Market’s Future Prospects?
In the iron deficiency injectables market, leading companies are innovating with new therapies like INJECTAFER to maintain their dominance. In June 2023, a reputable American healthcare company, Daiichi Sankyo Company, and a prominent injectables manufacturer based in the US, American Regent Inc., introduced INJECTAFER (ferric carboxymaltose injection) for iron deficiency, which earned the approval of the Food And Drug Administration, a US government agency. This marks the first and sole intravenous iron substitution therapy to receive FDA endorsement for adult patients suffering from chronic and progressive heart failure. Over 40 clinical trials including more than 8,800 participants from various countries have been carried out with INJECTAFER. The recent approval enhances INJECTAFER’s established success in treating these patients, namely adult and pediatric patients with iron-deficient anemia and heart failure.
Get Instant Access to the Global Iron Deficiency Injectable Market Report with Swift Delivery!
https://www.thebusinessresearchcompany.com/report/iron-deficiency-injectable-global-market-report
How Are the Key Segments of the Iron Deficiency Injectable Market Impacting Its Expansion and Revenue Streams?
The iron deficiency injectable market covered in this report is segmented –
1) By Type: Iron Dextran, Iron Sucrose, Ferric Carboxymaltose
2) By Branded or Generics: Branded, Generics
3) By Application: Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Other Applications
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Iron Dextran: Low Molecular Weight Iron Dextran, High Molecular Weight Iron Dextran
2) By Iron Sucrose: Venofer
3) By Ferric Carboxymaltose: Injectafer, Ferinject
What Regions Are Leading the Growth Trajectory of the Iron Deficiency Injectable Market?
North America was the largest region in the iron deficiency injectable market in 2024. The regions covered in iron deficiency injectable market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
What Are the Key Characteristics That Define the Iron Deficiency Injectable Market?
Iron deficiency refers to a condition where the body lacks adequate iron, leading to decreased production of red blood cells and hemoglobin. Iron deficiency injectables refer to injectable medications or solutions used to treat iron deficiency. These injectable forms of iron allow for direct delivery of the iron into the bloodstream, bypassing the digestive system.
Browse Through More Similar Reports By The Business Research Company:
Patient Blood Management Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/patient-blood-management-global-market-report
Hemoglobin Testing Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/hemoglobin-testing-global-market-report
Stem Cell/Cord Blood Banking Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/stem-cell-cord-blood-banking-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
